1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) &amp; nivolumab (nivo)

Rebecca Simpson; M. Batten; E.R. Shanahan; I. Pires da Silva; J.M. Versluis; I.L.M. Reijers; A.M. Menzies; R.P.M. Saw; M. Gonzalez; Kerwin F. Shannon; Andrew J. Spillane; C.U. Blank; Richard A Scolyer; G.V. Long

doi:10.1016/j.annonc.2022.07.1742

Related publications

Article2021

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Georgina V. Long, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Alexander Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Daniel J. Tenney, Hao Tang, Jeffrey S. Weber

Article2020

FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

Amir Iravani, Roslyn Wallace, Serigne Lo, Anna Galligan, Alison M. Weppler, George Au‐Yeung, Damien Kee, Peter K. H. Lau, Benjamin Brady, Belinda Lee, Grant A. McArthur, Shahneen Sandhu, Rodney J. Hicks

Article2018

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Elisa A. Rozeman, Alexander Christopher Jonathan Van Akkooi, Alexander M. Menzies, Myles Smith, Richard A Scolyer, Loes M. Pronk, Maria Gonzales, Christoph Höeller, Johan Hansson, James Larkin, Georgina V. Long, Christian U. Blank

Article2017

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Elisa A. Rozeman, Alexander Christopher Jonathan Van Akkooi, Émilie Routier, Alexander M. Menzies, Hanna Eriksson, Myles Smith, Richard A Scolyer, Christoph Höeller, Johan Hansson, Caroline Robert, James Larkin, Georgina V. Long, Christian U. Blank

Article2018

OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)

Christian U. Blank, Elisa A. Rozeman, Alexander M. Menzies, Bart A. van de Wiel, Chandra Mani Adhikari, Karolina Sikorska, Oscar Krijgsman, Hanna Eriksson, Carolien Bierman, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Annegien Broeks, Alexander Guminski, Andrew J. Spillane, W. Martin C. Klop, Robyn P.M. Saw, Richard A Scolyer, Alexander C.J. van Akkooi, Johan Hansson, Georgina V. Long

1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)

Discussion(0)

Related publications

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)

1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) &amp; nivolumab (nivo)

Discussion(0)

Related publications

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)

1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)